MAPT and Alzheimer disease: Furthermore, our data showed that among individuals with Braak stage III–VI, those with T2DM exhibited more p-Tau-ir in the NBM compared to the non-diabetic controls, suggesting that T2DM may exacerbate neuropathological changes associated with AD.